Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes

Journal of Cancer

Volumn 4, Issue 7, 2013, Pages 549-556

  Chae, Young Kwang ^a   Brown, Erika N ^b   Lei, Xiudong ^c   Melhem Bertrandt, Amal ^b   Giordano, Sharon H ^b   Litton, Jennifer K ^b   Hortobagyi, Gabriel N ^b   Gonzalez Angulo, Ana M ^b   Chavez MacGregor, Mariana ^b  

^a Division of Cancer Medicine   (United States)

^b Department of Breast Medical Oncology ^*  (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ace Inhibitor; Arb; Breast Cancer; Neoadjuvant Chemotherapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ENALAPRIL; EPIRUBICIN; IRBESARTAN; LISINOPRIL; PACLITAXEL; VALSARTAN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY TUMOR; RECURRENCE FREE SURVIVAL; SYSTEMIC THERAPY;

EID: 84883009175     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.6888     Document Type: Article

References (37)

1. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. Journal of managed care pharmacy : JMCP. 2007; 13: 9-20.
2. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nature reviews Cancer. 2010; 10: 745-59. doi:10.1038/nrc2945.
3. Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. Journal of human hypertension. 2009; 23: 623-35. doi:10.1038/jhh.2009.21.
4. Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation- related pathways. Laboratory investigation, a journal of technical methods and pathology. 2002; 82: 747-56.
5. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005; 11: 2686-94. doi:10.1158/1078-0432.CCR-04-1946.
6. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis. 2005; 26: 271-9. doi:10.1093/carcin/bgh324.
7. Otake AH, Mattar AL, Freitas HC, Machado CM, Nonogaki S, Fujihara CK, et al. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer chemotherapy and pharmacology. 2010; 66: 79-87. doi:10.1007/s00280-009-1136-0.
8. Ohnuma Y, Toda M, Fujita M, Hosono K, Suzuki T, Ogawa Y, et al. Blockade of an angiotensin type I receptor enhances effects of radiation on tumor growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2009; 63: 136-45. doi:10.1016/j.biopha.2007.11.005.
9. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998; 352: 179-84. doi:10.1016/S0140-6736(98)03228-0.
10. Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA, Trial V. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. Journal of the National Cancer Institute. 2008; 100: 1223-32. doi:10.1093/jnci/djn262.
11. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium- channel blockers and risk of cancer. Lancet. 1997; 349: 525-8. doi:10.1016/S0140-6736(97)80084-0.
12. Sjoberg T, Garcia Rodriguez LA, Lindblad M. Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2007; 5: 1160-6 e1. doi:10.1016/j.cgh.2007.08.005.
13. Control CfD. Cancer Incidence and Mortality Data. Center for Disease Control Journal for Clinicians, Cancer Statistics 2011. 2011.
14. Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R, et al. Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecologic oncology. 2008; 109: 418-25. doi:10.1016/j.ygyno.2008.02.019.
15. Greco S, Muscella A, Elia MG, Salvatore P, Storelli C, Mazzotta A, et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. Journal of cellular physiology. 2003; 196: 370-7. doi:10.1002/jcp.10313.
16. Puddefoot JR, Udeozo UK, Barker S, Vinson GP. The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion. Endocrine- related cancer. 2006; 13: 895-903. doi:10.1677/erc.1.01136.
17. Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106: 10284-9. doi:10.1073/pnas.0900351106.
18. Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. Journal of the American College of Surgeons. 1995; 180: 297-306.
19. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003; 9: 124-33.
20. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007; 25: 4414-22. doi:10.1200/JCO.2007.10.6823.
21. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of the National Cancer Institute Monographs. 2001;: 96-102.
22. O'Regan RM, Von Roenn JH, Carlson RW, Malik U, Sparano JA, Staradub V, et al. Final results of a phase II trial of preoperative TAC (docetaxel/ doxorubicin/cyclophosphamide) in stage III breast cancer. Clinical breast cancer. 2005; 6: 163-8. doi:10.3816/CBC.2005.n.019.
23. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. The Surgical clinics of North America. 2003; 83: 803-19. doi:10.1016/S0039-6109(03)00034-3.
24. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29: 2645-52. doi:10.1200/JCO.2010.33.4441.
25. Chavez-Macgregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E, et al. Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer. 2012; 118: 326-32. doi:10.1002/cncr.26144.
26. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009; 27: 3297-302. doi:10.1200/JCO.2009.19.6410.
27. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2012; 118: 1202-11. doi:10.1002/cncr.26439.
28. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Breast cancer. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2009; 7: 122-92.
29. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006; 24: 1037-44. doi:10.1200/JCO.2005.02.6914.
30. Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, et al. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer investigation. 2011; 29: 585-93. doi:10.3109/07357907.2011.616252.
31. Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast cancer research and treatment. 2011; 129: 549-56. doi:10.1007/s10549-011-1505-3.
32. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin- receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. The lancet oncology. 2010; 11: 627-36. doi:10.1016/S1470-2045(10)70106-6.
33. Yoon C, Yang HS, Jeon I, Chang Y, Park SM. Use of angiotensin- converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2011; 183: E1073-84. doi:10.1503/cmaj.101497.
34. Chang CH, Lin JW, Wu LC, Lai MS. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29: 3001-7. doi:10.1200/JCO.2011.35.1908.
35. Sugiura R, Ogawa H, Oka T, Koyanagi R, Hagiwara N, Investigators H-C. Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy). The American journal of cardiology. 2012; 109: 576-80. doi:10.1016/j.amjcard.2011.09.050.
36. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. The lancet oncology. 2011; 12: 65-82. doi:10.1016/S1470-2045(10)70260-6.
37. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010; 28: 1467-72. doi:10.1200/JCO.2009.22.7918.